甲状腺相关眼病的治疗进展  

Progress in the treatment of thyroid-associated ophthalmopathy

作　　者：李凯军[1] 何剑峰[1] LI Kaijun;HE Jianfeng(Department of Ophthalmology,First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院眼科,南宁530021

出　　处：《眼科学报》2019年第1期52-56,共5页Eye Science

摘　　要：甲状腺相关眼病是最常见的眼眶疾病,公认是一种自身免疫性疾病,因眶内免疫及增殖反应而致突眼、压迫性视神经病变等各种临床表现。近年眼科、内分泌科、核医学科、放疗科针对该疾病开展了一系列的临床研究,制定了相应的临床处理指南。研究显示,被转诊到三级中心的甲状腺相关眼病患者的严重度和活动性有下降的趋势,这可能与对该疾病认识的增强、甲亢和甲状腺相关眼病的早期诊断和治疗以及更有效地使用预防措施有关。但国内临床工作中碰到严重的甲状腺相关眼病患者反有增加的趋势,这可能与临床对该疾病的重视和规范化诊治程度不够有关。Thyroid-associated ophthalmopathy is the most common orbital disease. It is recognized as an autoimmune disease, which causes exophthalmos, oppressive optic neuropathy and other clinical manifestations due to infraorbital immunity and proliferation reaction. In recent years, ophthalmologists, endocrinologists, nuclear medicine doctors and radiotherapists have carried out a series of clinical studies on the disease and formulated corresponding clinical treatment guidelines. Overseas reports indicate that the severity and activity of thyroidassociated ophthalmopathy patients referred to tertiary centers are declining, which may be related to increased awareness of the disease, early diagnosis and treatment of hyperthyroidism and thyroid-associated ophthalmopathy, and more effective use of preventive measures. However, the number of patients with severe thyroid-associated ophthalmopathy is increasing in our clinical work, which may be related to our lack of attention to the disease and standardized diagnosis and treatment.

关 键 词：甲状腺相关眼病 大剂量激素冲击治疗 眼眶减压手术 

分 类 号：R581[医药卫生—内分泌] R771.3[医药卫生—内科学]